Case Studies for Overcoming Challenges in Using Big Data in Cancer.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
14 04 2023
14 04 2023
Historique:
received:
15
04
2022
revised:
29
07
2022
accepted:
06
12
2022
medline:
17
4
2023
pubmed:
11
1
2023
entrez:
10
1
2023
Statut:
ppublish
Résumé
The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context of precision medicine. However, there are challenges in organizing, sharing, integrating, and making these data readily accessible to the research community. This review presents five case studies illustrating various successful approaches to addressing such challenges. These efforts are CancerLinQ, the American Association for Cancer Research Project GENIE, Project Data Sphere, the National Cancer Institute Genomic Data Commons, and the Veterans Health Administration Clinical Data Initiative. Critical factors in the development of these systems include attention to the use of robust pipelines for data aggregation, common data models, data deidentification to enable multiple uses, integration of data collection into physician workflows, terminology standardization and attention to interoperability, extensive quality assurance and quality control activity, incorporation of multiple data types, and understanding how data resources can be best applied. By describing some of the emerging resources, we hope to inspire consideration of the secondary use of such data at the earliest possible step to ensure the proper sharing of data in order to generate insights that advance the understanding and the treatment of cancer.
Identifiants
pubmed: 36625851
pii: 712813
doi: 10.1158/0008-5472.CAN-22-1277
pmc: PMC10102839
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1183-1190Informations de copyright
©2023 The Authors; Published by the American Association for Cancer Research.
Références
Oncologist. 2015 May;20(5):464-e20
pubmed: 25876994
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Trends Genet. 2019 Mar;35(3):223-234
pubmed: 30691868
JCO Clin Cancer Inform. 2020 Oct;4:929-937
pubmed: 33104389
Sci Data. 2016 Mar 15;3:160018
pubmed: 26978244
Annu Rev Genomics Hum Genet. 2018 Aug 31;19:429-453
pubmed: 29400986
Cancer Res. 2023 Apr 14;83(8):1175-1182
pubmed: 36625843
Nat Commun. 2021 Feb 22;12(1):1226
pubmed: 33619257
Nat Genet. 2021 Mar;53(3):257-262
pubmed: 33619384
N Engl J Med. 2017 Mar 23;376(12):1178-1181
pubmed: 28328337
Clin Pharmacol Ther. 2017 May;101(5):619-621
pubmed: 28187513
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Lancet Oncol. 2017 Jan;18(1):132-142
pubmed: 27864015
J Digit Imaging. 2013 Dec;26(6):1045-57
pubmed: 23884657
JCO Clin Cancer Inform. 2018 Dec;2:1-14
pubmed: 30652542
JCO Clin Cancer Inform. 2017 Nov;1:1-15
pubmed: 30657384
Blood. 2017 Jul 27;130(4):453-459
pubmed: 28600341
Cancer Res. 2017 Nov 1;77(21):e15-e18
pubmed: 29092930
Cancer Discov. 2020 Apr;10(4):526-535
pubmed: 31924700
J Clin Epidemiol. 2016 Feb;70:214-23
pubmed: 26441289
Health Aff (Millwood). 2014 Jul;33(7):1203-11
pubmed: 25006147
Semin Oncol. 2019 Aug - Oct;46(4-5):314-320
pubmed: 31629530
J Clin Oncol. 2014 Aug 1;32(22):2373-9
pubmed: 24912897
Lancet Oncol. 2017 Jan;18(1):143-154
pubmed: 27979599